Foundation Supports Pursuit of FDA Approval for CF Drug by Gilead
September 17, 2008
The Cystic Fibrosis Foundation is disappointed that a potential new and much-needed antibiotic treatment for cystic fibrosis, aztreonam lysine for inhalation, will not be available to patients as quickly as anticipated.
The Foundation is prepared to work with Gilead Sciences, Inc. in their efforts to illustrate the vital role that this drug can play in the treatment of the major cause of morbidity and mortality in cystic fibrosis and the need for approval at the earliest possible date.
In addition, if the Food and Drug Administration ultimately decides that another clinical trial is necessary, the Foundation is prepared to work with Gilead Sciences, Inc. and the CF community to facilitate the completion of the trial.
Read Gilead's release.